Clinical trials
Leiomyosarcoma clinical trials
Below are recruiting leiomyosarcoma clinical trials, each written for real people, not researchers. We’re tracking 38 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT01793168Recruiting
Rare disease registry and history study
This study keeps a registry (a structured list) of people with rare diseases and may also track how the condition changes over time. It can help researchers better understand rare illnesses and find gaps in care, which may improve future treatments.
Sioux Falls, South DakotaAges Any age - NCT06571734RecruitingPhase 2
XL092 for advanced sarcoma types
This trial tests an experimental drug called XL092 (zanzalintinib) for people with advanced leiomyosarcoma, bone sarcoma, or translocation-associated soft tissue sarcoma that has spread or cannot be removed by surgery. The drug is a type of targeted therapy that may stop cancer growth.
Chicago, IllinoisAges 18 years+ - NCT06524583RecruitingPhase 2
Chemotherapy after surgery for high-risk uterine leiomyosarcoma
This trial tests whether chemotherapy after surgery can help prevent uterine leiomyosarcoma from coming back in patients who are at high risk based on a genetic test of their tumor. It is for women with early-stage cancer (stage I) who have had complete surgery.
AngersAges 18–75 - NCT07405346Enrolling by invitation
Organoid-guided treatment for advanced leiomyosarcoma
This trial uses your tumor's lab-grown organoids to find the most effective personalized treatment for advanced leiomyosarcoma. It aims to match you with a drug that targets your specific cancer.
Wuhan, HubeiAges 18–75 - NCT05649956RecruitingPhase 2
Letrozole after surgery for early uterine leiomyosarcoma
This Phase 2 trial studies whether letrozole can help prevent uterine leiomyosarcoma from coming back after surgery. It focuses on people whose tumor shows estrogen receptor positivity.
Aurora, ColoradoAges 18 years+ - NCT06239272RecruitingPhase 1/Phase 2
Personalized treatment for NRSTS in children and young adults
This trial tests a personalized treatment plan for children and young adults with a type of soft tissue sarcoma (NRSTS). It uses a combination of surgery, targeted radiation, and two drugs (pazopanib and selinexor) to fight cancer while reducing side effects. The study is looking for people who have not been treated before for this sarcoma.
Atlanta, GeorgiaAges Up to 30 years - NCT07633756RecruitingPhase 1
Testing RB1-negative Leiomyosarcoma Treatment with REC-617
This study tests a new drug called REC-617 in patients with a rare muscle cancer (leiomyosarcoma) that has spread or cannot be surgically removed. The drug targets cancer cells that lack a specific protein called RB1, and you must have already tried at least one other cancer treatment before joining.
Houston, TexasAges 18 years+ - NCT03016819RecruitingPhase 3
Test drugs anlotinib and catequentinib for advanced sarcoma
This Phase 3 study tests two anti-cancer medicines (anlotinib and catequentinib) for people with certain advanced soft-tissue sarcomas, including alveolar soft part sarcoma, synovial sarcoma, and leiomyosarcoma. It is designed for tumors that cannot be removed and that have either grown despite treatment or no longer respond to standard options.
Phoenix, ArizonaAges 18 years+ - NCT04383119RecruitingPhase 2
Study for advanced leiomyosarcoma after prior chemo
This Phase 2 trial studies how well gemcitabine or trabectedin works for people with leiomyosarcoma that cannot be fully removed or has spread. It’s for tumors that have grown or worsened despite prior standard chemotherapy.
Bologna, BOAges 18 years+ - NCT05653388Recruiting
Study biomarker testing in metastatic leiomyosarcoma
This trial looks at lab markers (biomarkers) in tumor samples from people with leiomyosarcoma that has spread or can’t be fully removed. It also enrolls people who are receiving certain first-line chemotherapy, and your results may help guide future treatment decisions.
Santa Monica, CaliforniaAges Any age - NCT05711615RecruitingPhase 1
Low-dose doxorubicin plus peposertib for advanced sarcoma
This Phase 1 trial tests a low dose of a common chemotherapy (liposomal doxorubicin) together with an anti-cancer drug called peposertib. It’s for people with advanced sarcoma that can’t be cured, aiming to find a safe dosing plan and see how well the treatment might work.
Los Angeles, CaliforniaAges 18 years+ - NCT06308419RecruitingPhase 1
Combination gemcitabine and nab-sirolimus for advanced sarcoma
This trial tests a combination of two drugs—gemcitabine (a chemotherapy drug) and nab-sirolimus (a targeted therapy)—for people with advanced soft-tissue sarcoma or leiomyosarcoma, especially those whose tumors have a specific genetic change in the TSC2 or TSC1 genes. The goal is to see if this combination can shrink tumors or slow their growth.
Houston, TexasAges 18 years+ - NCT06498648RecruitingPhase 1/Phase 2
Abemaciclib with gemcitabine for soft tissue sarcoma
This trial tests whether adding the targeted drug abemaciclib to standard chemotherapy (gemcitabine) works better against certain soft tissue sarcomas. It is for people whose tumors have a normal Rb gene, which may help the drug work.
Houston, TexasAges 18 years+ - NCT06528769RecruitingPhase 2
ATRA and immunotherapy for advanced leiomyosarcoma
This trial tests a combination of two drugs—all-trans retinoic acid (ATRA, a vitamin A derivative) and cemiplimab (an immunotherapy)—for people with advanced leiomyosarcoma who've already had chemotherapy. The goal is to see if this combination can shrink tumors or slow cancer growth.
Columbus, OhioAges 18 years+ - NCT06749600Recruiting
Study on ovarian leiomyosarcoma outcomes
This study looks at the medical care and results for people diagnosed with a rare type of ovarian cancer called primary ovarian leiomyosarcoma (POLMS). It aims to learn more about the disease and how it's managed.
Modena, ItalyAges 18–99 - NCT06789172RecruitingPhase 1
New drug OKN4395 with or without pembrolizumab for solid tumors
This trial tests a new oral drug called OKN4395, which targets a COX2-related immune pathway, alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors. It may be an option if you have certain types of cancer that have stopped responding to other treatments.
Beverly Hills, CaliforniaAges 18 years+ - NCT06957431RecruitingPhase 1
Zanzalintinib and eribulin for advanced leiomyosarcoma and liposarcoma
This trial tests a combination of two drugs, zanzalintinib and eribulin, for people with advanced leiomyosarcoma or liposarcoma that has progressed after prior treatment. The goal is to see if this combination can help shrink or slow the growth of these sarcomas.
St Louis, MissouriAges 18 years+ - NCT04925089Recruiting
Testing biomarkers in localized soft tissue cancer before surgery
This study looks at lab biomarkers (signs in tumor tissue) in people with localized leiomyosarcoma. It also requires treatment with chemotherapy before surgery to see if the information from tumor samples can help guide care.
Ann Arbor, MichiganAges Any age - NCT07516925RecruitingPhase 2
Ivonescimab for Advanced Leiomyosarcoma
This trial tests a new immunotherapy drug called ivonescimab in people with leiomyosarcoma (a rare soft-tissue cancer) that cannot be surgically removed or has spread. The drug works by helping your immune system recognize and fight cancer cells.
Basking Ridge, New JerseyAges 18 years+ - NCT06975293RecruitingPhase 1/Phase 2
STC-15 with toripalimab for advanced cancers and sarcomas
This trial tests a new drug called STC-15, either alone or with another drug (toripalimab), for people with certain advanced cancers or sarcomas that have progressed after prior treatment. The goal is to see if this combination or single drug can help shrink tumors or slow the disease.
San Francisco, CaliforniaAges 18 years+ - NCT07076186RecruitingPhase 2
Study of two chemotherapy drugs after surgery for uterine leiomyosarcoma
This trial is testing a combination of two chemotherapy drugs (doxorubicin and trabectedin) given after surgery to prevent uterine leiomyosarcoma from coming back. The goal is to see if this treatment improves outcomes for patients with high-risk disease that has not spread.
Houston, TexasAges 18 years+ - NCT05227326RecruitingPhase 1
A new drug for solid cancers that did not respond to usual care
This early-stage (Phase 1) trial tests AOH1996 in adults with solid tumors that have stopped responding to standard treatments. It’s meant to find a safe dose and see if the drug can help, especially in cancers with limited options.
Scottsdale, ArizonaAges 18 years+ - NCT04031677RecruitingPhase 3
Surgery with or without chemotherapy for high-risk retroperitoneal sarcoma
This trial studies whether adding chemotherapy before surgery helps people with high-risk retroperitoneal (abdominal-area) leiomyosarcoma or liposarcoma. The goal is to improve outcomes while comparing surgery alone versus surgery plus neoadjuvant chemotherapy.
Birmingham, AlabamaAges 18 years+ - NCT04055220Recruiting
Regorafenib to keep bone cancer from coming back
This trial studies whether regorafenib given after first treatment helps patients with bone sarcoma stay in remission longer. It focuses on safety and whether the medicine can prevent the cancer from growing or returning.
BesançonAges 12 years+
Hear when a new Leiomyosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Leiomyosarcoma trials by city
Studies with a site in or near these metro areas.
Leiomyosarcoma trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for leiomyosarcoma?
- Yes. Clin2 currently lists 38 recruiting leiomyosarcoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a leiomyosarcoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a leiomyosarcoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.